Potent Activities of Luliconazole, Lanoconazole, and Eight Comparators against Molecularly Characterized Fusarium Species

ABSTRACT A collection of clinical (n = 47) and environmental (n = 79) Fusarium isolates were tested against 10 antifungal drugs, including 2 novel imidazoles. Luliconazole and lanoconazole demonstrated very low geometric mean MIC values of 0.005 and 0.013 μg/ml, respectively, compared with 0.51 μg/ml for micafungin, 0.85 μg/ml for efinaconazole, 1.12 μg/ml for natamycin, 1.18 μg/ml for anidulafungin, 1.31 μg/ml for voriconazole, 1.35 μg/ml for caspofungin, 1.9 μg/ml for amphotericin B, and 4.08 μg/ml for itraconazole. Results show that these drugs are potential candidates for (topical) treatment of skin and nail infections due to Fusarium species.

[1]  H. Badali,et al.  In vitro antifungal activity of amphotericin B and 11 comparators against Aspergillus terreus species complex , 2018, Mycoses.

[2]  S. Ranque,et al.  Current antifungal treatment of fusariosis. , 2017, International journal of antimicrobial agents.

[3]  H. Badali,et al.  In Vitro Activities of Luliconazole, Lanoconazole, and Efinaconazole Compared with Those of Five Antifungal Drugs against Melanized Fungi and Relatives , 2017, Antimicrobial Agents and Chemotherapy.

[4]  Savitri Sharma,et al.  An Assessment of In Vitro Antifungal Activities of Efinaconazole and Itraconazole against Common Non-Dermatophyte Fungi Causing Onychomycosis , 2017, Journal of fungi.

[5]  S. Ranque,et al.  Comparative Evaluation of Etest, EUCAST, and CLSI Methods for Amphotericin B, Voriconazole, and Posaconazole against Clinically Relevant Fusarium Species , 2016, Antimicrobial Agents and Chemotherapy.

[6]  H. Badali,et al.  In vitro activity of new azoles luliconazole and lanoconazole compared with ten other antifungal drugs against clinical dermatophyte isolates. , 2016, Medical mycology.

[7]  H. Badali,et al.  Potent Activities of Novel Imidazoles Lanoconazole and Luliconazole against a Collection of Azole-Resistant and -Susceptible Aspergillus fumigatus Strains , 2016, Antimicrobial Agents and Chemotherapy.

[8]  T. Boekhout,et al.  In vitro resistance of clinical Fusarium species to amphotericin B and voriconazole using the EUCAST antifungal susceptibility method. , 2016, Diagnostic microbiology and infectious disease.

[9]  J. Meis,et al.  In vitro combinations of natamycin with voriconazole, itraconazole and micafungin against clinical Fusarium strains causing keratitis. , 2016, The Journal of antimicrobial chemotherapy.

[10]  J. Meis,et al.  Fusarium: Molecular Diversity and Intrinsic Drug Resistance , 2016, PLoS pathogens.

[11]  J. Meis,et al.  Global molecular epidemiology and genetic diversity of Fusarium, a significant emerging group of human opportunists from 1958 to 2015 , 2016, Emerging microbes & infections.

[12]  A. A. Hatmi.  Phylogeny, diagnostics and antifungal susceptibility of clinically relevant Fusarium species , 2016 .

[13]  M. Ghannoum,et al.  International Evaluation of MIC Distributions and Epidemiological Cutoff Value (ECV) Definitions for Fusarium Species Identified by Molecular Methods for the CLSI Broth Microdilution Method , 2015, Antimicrobial Agents and Chemotherapy.

[14]  F. Marty,et al.  Invasive Fusariosis in the Voriconazole Era: Single-Center 13-Year Experience , 2015, Open forum infectious diseases.

[15]  J. Meis,et al.  Specific antifungal susceptibility profiles of opportunists in the Fusarium fujikuroi complex. , 2014, The Journal of antimicrobial chemotherapy.

[16]  D. Khanna,et al.  Luliconazole for the treatment of fungal infections: an evidence-based review , 2014, Core evidence.

[17]  M. Caira,et al.  European Confederation of Medical Mycology (ECMM) epidemiological survey on invasive infections due to Fusarium species in Europe , 2014, European Journal of Clinical Microbiology & Infectious Diseases.

[18]  L. Pagano,et al.  ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[19]  Springer-Verlag,et al.  Fusariosis, a complex infection caused by a high diversity of fungal species refractory to treatment , 2013, European Journal of Clinical Microbiology & Infectious Diseases.

[20]  S. Botton,et al.  Synergysm of voriconazole or itraconazole with other antifungal agents against species of Fusarium. , 2013, Revista iberoamericana de micologia.

[21]  A. Fothergill,et al.  Comparison of In Vitro Antifungal Activities of Efinaconazole and Currently Available Antifungal Agents against a Variety of Pathogenic Fungi Associated with Onychomycosis , 2013, Antimicrobial Agents and Chemotherapy.

[22]  E. Mylonakis,et al.  The challenge of managing fusariosis , 2011, Virulence.

[23]  N. Osherov,et al.  In vitro synergy of caspofungin with licensed and novel antifungal drugs against clinical isolates of Fusarium spp. , 2009, Medical mycology.

[24]  G. González.  In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi. , 2009, Medical mycology.

[25]  J. Guarro,et al.  In Vitro Antifungal Susceptibility and Molecular Characterization of Clinical Isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum , 2008, Antimicrobial Agents and Chemotherapy.

[26]  E. Mellado,et al.  Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods. , 2008, The Journal of antimicrobial chemotherapy.

[27]  Clinical,et al.  Reference method for broth dilution antifungal susceptibility testing of filamentous fungi : Approved standard , 2008 .

[28]  R. Bajo,et al.  Resolution of disseminated fusariosis in a child with acute leukemia treated with combined antifungal therapy: a case report , 2007, BMC infectious diseases.

[29]  J. Lee,et al.  Treating disseminated fusariosis: amphotericin B, voriconazole or both? , 2007, Mycoses.

[30]  E. Boutati,et al.  Resolution of fungemia due to Fusarium species in a patient with acute leukemia treated with caspofungin. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  H. Yamaguchi,et al.  In vitro activity of novel imidazole antifungal agent NND-502 against Malassezia species. , 2003, International journal of antimicrobial agents.